Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company

Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins

Fineline Cube Aug 27, 2024

Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control

Fineline Cube Aug 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Drug

China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors

Fineline Cube Aug 26, 2024

The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude...

Company Medical Device

Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions

Fineline Cube Aug 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...

Company Drug

Mabwell Bioscience Initiates Phase III Trial for 9MW2821 Combo in Urothelial Carcinoma Following NMPA Clearance

Fineline Cube Aug 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has announced...

Company

CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones

Fineline Cube Aug 26, 2024

CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals Medical Device

Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round

Fineline Cube Aug 26, 2024

Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...

Company Drug

US FDA Approves Updated COVID-19 mRNA Vaccines from Pfizer/BioNTech and Moderna Ahead of Winter

Fineline Cube Aug 26, 2024

The U.S. Food and Drug Administration (FDA) has granted approval to two updated mRNA COVID-19...

Company

Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals

Fineline Cube Aug 26, 2024

Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange...

Company Medical Device

National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers

Fineline Cube Aug 26, 2024

The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and...

Company Drug

Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma

Fineline Cube Aug 26, 2024

Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...

Company Drug

Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach

Fineline Cube Aug 26, 2024

Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...

Policy / Regulatory

China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments

Fineline Cube Aug 26, 2024

The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State...

Company Drug

Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments

Fineline Cube Aug 23, 2024

Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors

Fineline Cube Aug 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...

Company Drug

Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE

Fineline Cube Aug 23, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...

Company Deals

ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal

Fineline Cube Aug 23, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...

Company Drug

Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease

Fineline Cube Aug 23, 2024

Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301...

Company Drug

Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy

Fineline Cube Aug 23, 2024

Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...

Company

Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers

Fineline Cube Aug 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...

Posts pagination

1 … 255 256 257 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.